AU2358788A - The use of GM-CSF in the treatment of a patient requiring high-dose chemo- or radiotherapy for cancer - Google Patents

The use of GM-CSF in the treatment of a patient requiring high-dose chemo- or radiotherapy for cancer

Info

Publication number
AU2358788A
AU2358788A AU23587/88A AU2358788A AU2358788A AU 2358788 A AU2358788 A AU 2358788A AU 23587/88 A AU23587/88 A AU 23587/88A AU 2358788 A AU2358788 A AU 2358788A AU 2358788 A AU2358788 A AU 2358788A
Authority
AU
Australia
Prior art keywords
radiotherapy
csf
cancer
treatment
requiring high
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU23587/88A
Other versions
AU618283B2 (en
Inventor
Alessandro M. Gianni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Istituto Nazionale per lo Studio e la Cura die Tumori
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Priority to AU23587/88A priority Critical patent/AU618283B2/en
Publication of AU2358788A publication Critical patent/AU2358788A/en
Application granted granted Critical
Publication of AU618283B2 publication Critical patent/AU618283B2/en
Assigned to INSTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI, NOVARTIS AG reassignment INSTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI Request to Amend Deed and Register Assignors: INSTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI, SANDOZ LTD.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU23587/88A 1988-10-10 1988-10-10 The use of GM-CSF in the treatment of a patient requiring high-dose chemo- or radiotherapy for cancer Expired AU618283B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU23587/88A AU618283B2 (en) 1988-10-10 1988-10-10 The use of GM-CSF in the treatment of a patient requiring high-dose chemo- or radiotherapy for cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU23587/88A AU618283B2 (en) 1988-10-10 1988-10-10 The use of GM-CSF in the treatment of a patient requiring high-dose chemo- or radiotherapy for cancer

Publications (2)

Publication Number Publication Date
AU2358788A true AU2358788A (en) 1990-04-12
AU618283B2 AU618283B2 (en) 1991-12-19

Family

ID=3712663

Family Applications (1)

Application Number Title Priority Date Filing Date
AU23587/88A Expired AU618283B2 (en) 1988-10-10 1988-10-10 The use of GM-CSF in the treatment of a patient requiring high-dose chemo- or radiotherapy for cancer

Country Status (1)

Country Link
AU (1) AU618283B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025228A1 (en) * 1992-06-15 1993-12-23 Whittier Institute For Diabetes And Endocrinology Cytotoxins specific for gm-csf receptor-bearing cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR851643B (en) * 1984-07-06 1985-11-26 Sandoz Ag

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025228A1 (en) * 1992-06-15 1993-12-23 Whittier Institute For Diabetes And Endocrinology Cytotoxins specific for gm-csf receptor-bearing cells

Also Published As

Publication number Publication date
AU618283B2 (en) 1991-12-19

Similar Documents

Publication Publication Date Title
AU640772B2 (en) Catheter for extracorporeal treatment
AU7813191A (en) Novel immunoconjugates and methods for their use in tumor therapy
HK1006676A1 (en) Immunoconjugates for cancer diagnosis and therapy
AU8317587A (en) Therapeutic preparations
EP0378692A4 (en) Catheter for medical treatment
AU2140492A (en) Use of hemoglobin in a method for the treatment of tumors with chemotherapeutic agents
AU3129993A (en) Localized oligonucleotide therapy
AU623031B2 (en) Catheter and assembly for extracorporeal circulation
AU588862B2 (en) Human tumor therapy
EP0564121A3 (en) Formulation for the treatment of cancer comprising a bacterial extract
AU3133889A (en) Method for the treatment of the extraphyramidal side effects associated with neuroleptic therapy
IL103438A0 (en) Extracorporeal therapy apparatus
AU3066789A (en) Optically pure r-(-)-niguldipine and its derivatives for treating tumorous diseases
AU1346488A (en) Arginine-depleted human tumor necrosis factor
EP0280593A3 (en) Composition on the basis of an amino-acid and vitamins for use in cancer therapy
EP0370115A4 (en) Catheter for diagnosis and therapy
AU2358788A (en) The use of GM-CSF in the treatment of a patient requiring high-dose chemo- or radiotherapy for cancer
AU3434489A (en) Skin treatment formulations
ZA922073B (en) New compounds for use in the treatment of cancer
AU3510489A (en) Pharmaceutical composition for treating tumor
AU4825993A (en) New compounds for use in the treatment of cancer
AU2884092A (en) Epidermal growth factor therapy for non-gastroduodenal lesions
ZA899631B (en) Cancer treatment
SG115593G (en) Porphyrins and medicaments for cancer treatment
AU1704088A (en) Therapeutic treatment pad